Article Text

Download PDFPDF

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
  1. Heddy Bartell1,
  2. Jedd Wolchok2,
  3. F Stephen Hodi3,
  4. Helen Liu4,
  5. Cynthia Wojtaszek5 and
  6. Jeffrey Weber6
  1. Aff1 grid.419971.3Bristol-Myers Squibb Plainsboro NJ USA
  2. Aff2 grid.51462.340000000121719952Memorial Sloan Kettering Cancer Center New York NY USA
  3. Aff3 grid.65499.370000000121069910Dana-Farber Cancer Institute Boston MA USA
  4. Aff4 grid.419971.3Bristol-Myers Squibb Princeton NJ USA
  5. Aff5 grid.419971.3Bristol-Myers Squibb jackson NJ USA
  6. Aff6 grid.170693.a000000012353285XH. Lee Moffitt Cancer Center Tampa FL USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


IPI (Yervoy®, Bristol-Myers Squibb) blocks cytotoxic T-lymphocyte antigen-4, a regulatory molecule on activated T cells. In March 2011, IPI, indicated for unresectable or metastatic melanoma (MEL), became the first immune checkpoint inhibitor approved by the US Food and Drug Administration (FDA). Early in development, severe and fatal immune-related adverse events (irAEs) emerged and were attributed to IPI's mechanism of action, occurring mostly during treatment, although a minority occurred weeks to months after drug discontinuation. irAE management guidelines created in collaboration with external experts and study investigators were progressively incorporated into the IPI Investigator's Brochure.


At approval, the FDA stipulated that a Risk Evaluation and Mitigation Strategy (REMS) communication plan directed at healthcare providers (HCPs) be developed to ensure that benefits with IPI outweighed irAE risks. The REMS goal was to inform HCPs about serious risks with IPI and irAE management. Multichannel educational outreach to HCPs was implemented at launch and every 6 months for 3 years, in addition to a dedicated webpage and triggered outreach to new prescribers. REMS materials included a Dear HCP Letter, management guide, nursing checklist, and patient (pt) wallet card. Audience was HCPs who manage pts with MEL (eg, oncologists) and HCPs who may be consulted about irAEs (eg, gastroenterologists). Professional medical societies were also contacted to inform their memberships.


During the 3-year outreach effort, REMS materials were distributed via >160,000–250,000 emails per outreach and >700,000 total mailings. Prescriber understanding of irAE management was assessed twice, via oncologist knowledge surveys, with median correct scores of 76% in 2012 and 85% in 2014. Academic and community HCPs tested equally well. Pharmacovigilance review of fatal irAEs showed no delay in recognizing and treating irAEs, and management was consistent with US prescribing information. Periodic, aggregate safety data did not identify any new safety concerns. Because the REMS met its goal and key activities were successfully completed with no required modifications at the 18-month and the 3-year assessments, the FDA released the REMS in March 2015. Voluntary IPI safety education efforts continue worldwide.


Management algorithms and safety education materials were created through early collaboration with investigators and then broadly disseminated through the IPI REMS, increasing HCP awareness of irAE management. Socialization of irAE identification and management through the sentinel IPI safety education experience has benefited newer immuno-oncology agents, and IPI safety materials remain highly regarded and utilized by HCPs.